Marx Joannes J M, Kartikasari Apriliana E R, Georgiou Niki A
Eijkman Winkler Institute, University Medical Centre Utrecht, Utrecht, The Netherlands.
Hemoglobin. 2008;32(1-2):123-34. doi: 10.1080/03630260701726871.
Epidemiological studies and experimental data suggest iron involvement in atherosclerosis. The relation between iron and atherosclerosis is complex and remains contradictory. In thalassemia patients, non transferrin bound iron (NTBI) and free hemoglobin (Hb) are present in plasma and may accelerate atherogenesis, but its progression may be inhibited by iron chelators. The mechanism whereby iron may stimulate atherogenesis has been intensively investigated. Non transferrin bound iron and sera from subjects with hemochromatosis induced endothelial activation with expression of vascular adhesion molecules and endothelial inflammatory chemokines. Such events could be inhibited by iron chelators and oxygen radical scavengers with intracellular activity. Iron chelators may be effective in preventing vascular damage in patients with high concentrations of NTBI as found in thalassemia.
流行病学研究和实验数据表明铁与动脉粥样硬化有关。铁与动脉粥样硬化之间的关系复杂且仍存在矛盾。在地中海贫血患者中，血浆中存在非转铁蛋白结合铁（NTBI）和游离血红蛋白（Hb），它们可能加速动脉粥样硬化的发生，但其进展可能被铁螯合剂抑制。铁刺激动脉粥样硬化发生的机制已得到深入研究。非转铁蛋白结合铁和血色素沉着症患者的血清可诱导内皮细胞活化，伴有血管黏附分子和内皮炎症趋化因子的表达。此类事件可被具有细胞内活性的铁螯合剂和氧自由基清除剂抑制。正如在地中海贫血患者中发现的那样，铁螯合剂可能对预防高浓度NTBI患者的血管损伤有效。
